Effects of HMGA2 on malignant degree, invasion, metastasis, proliferation and cellular morphology of ovarian cancer cells

Asian Pacific Journal of Tropical Medicine

Volumn 7, Issue 4, 2014, Pages 289-292

  Xi, Yan Ni ^a   Xin, Xiao Yan ^b   Ye, Hong Mei ^a  

^a Second Hospital of Yulin City   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

High mobility group AT hook 2; Invasion; Morphology; Ovarian cancer; Proliferation

Indexed keywords

HIGH MOBILITY GROUP AT-HOOK 2; INVASION; MORPHOLOGY; OVARIAN CANCER; PROLIFERATION;

CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL SHAPE; FEMALE; HMGA2 PROTEIN; HUMANS; NEOPLASM INVASIVENESS; OVARIAN NEOPLASMS; RNA, SMALL INTERFERING;

EID: 84893454516     PISSN: 19957645     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1995-7645(14)60040-7     Document Type: Article

References (30)

1. Van Jaarsveld M, Helleman J, Berns EMJJ, Wiemer EAC MicroRNAs in ovarian cancer biology and therapy resistance. Intl J Biochem & Cell Biol 2010, 42(8):1282-1290.
2. Malek A, Tchernitsa O Evaluation of targets for ovarian cancer gene silencing therapy: in vitro and in vivo approaches. Methods Mol Biol 2010, 623:423-436.
3. Mahajan A, Liu Z, Gellert L, Zou X, Yang G, Lee P, et al. HMGA2: a biomarker significantly overexpressed in high-grade ovarian serous carcinoma. Modern Pathol 2010, 23(5):673-681.
4. Mezzanzanica D, Bagnoli M, De Cecco L, Valeri B, Canevari S Role of microRNAs in ovarian cancer pathogenesis and potential clinical implications. Int J Biochem & Cell Biol 2010, 42(8):1262-1272.
5. Boyerinas B, Park SM, Murmann AE, Gwin K, Montag AG, Zillhardt M, et al. Let-7 modulates acquired resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of multidrug resistance 1. Intl J Cancer 2012, 130(8):1787-1797.
6. Hetland TE, Nymoen DA, Holth A, Brusegard K, Flørenes VA, Kærn J, et al. HMGA2 protein expression in ovarian serous carcinoma effusions, primary tumors, and solid metastases. Virchows Archiv 2012, 460(5):505-513.
7. Bayani J, Kuzmanov U, Saraon P, Fung WA, Soosaipillai A, Squire JA, et al. Copy number and expression alterations of miRNAs in the ovarian cancer cell line OVCAR-3: Impact on Kallikrein 6 protein expression. Clin Chem 2013, 59(1):296-305.
8. Weirauch U, Gutsch D, Höbel S, Aigner A Polymer-based delivery of rna-based therapeutics in ovarian cancer. Methods Mol Biol 2013, 1049:443-465.
9. Boyerinas B, Park SM, Hau A, Murmann AE, Peter ME The role of let-7 in cell differentiation and cancer. Endocrine-related Cancer 2010, 17(1):F19-F36.
10. Kim TH, Kim YK, Kwon Y, Heo JH, Kang H, Kim G, et al. Deregulation of miR-519a, 153, and 485-5p and its clinicopathological relevance in ovarian epithelial tumours. Histopathology 2010, 57(5):734-743.
11. Lu L, Schwartz P, Scarampi L, Rutherford T, Canuto EM, Yu H, et al. MicroRNA let-7a: a potential marker for selection of paclitaxel in ovarian cancer management. Gynecologic Oncol 2011, 122(2):366-371.
12. McCluggage WG, Connolly LE, McBride HA, Kalloger S, Gilks CB HMGA2 is commonly expressed in uterine serous carcinomas and is a useful adjunct to diagnosis. Histopathology 2012, 60(4):547-553.
13. Kwon MJ, Shin YK Epigenetic regulation of cancer-associated genes in ovarian cancer. Int J Molecular Sci 2011, 12(2):983-1008.
14. Harter P, Hilpert F, Mahner S, Heitz F, Pfisterer J, du Bois A Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs. Expert Rev Anticancer Ther 2010, 10(1):81-88.
15. Bose CK Anomalous endocrine feedback of peri-menopause in the etiology of type II ovarian cancer. Future Oncol 2013, 9(9):1257-1261.
16. Davidson B, Smith Y, Nesland JM, Kærn J, Reich R, Tropè CG Defining a prognostic marker panel for patients with ovarian serous carcinoma effusion. Human Pathol 2013, 44(11):2449-2460.
17. Mezzanzanica D, Canevari S, Cecco LD, Bagnoli M miRNA control of apoptotic programs: focus on ovarian cancer. Expert Rev Mol Diagnostics 2011, 11(3):277-286.
18. Peter ME Let-7 and miR-200 microRNAs: guardians against pluripotency and cancer progression. Cell Cycle 2009, 8(6):843-852.
19. Verhaak RGW, Tamayo P, Yang JY, Hubbard D, Zhang H, Creighton CJ, et al. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clinical Invest 2013, 123(1):517.
20. Zaman MS, Maher DM, Khan S, Jaggi M, Chauhan SC Current status and implications of microRNAs in ovarian cancer diagnosis and therapy. J Ovarian Res 2012, 5(1):44.
21. Kenny SL, McBride HA, Jamison J, McCluggage WG Mesonephric adenocarcinomas of the uterine cervix and corpus: HPV-negative neoplasms that are commonly PAX8, CA125, and HMGA2 positive and that may be immunoreactive with TTF1 and hepatocyte nuclear factor 1-β. American J Surgical Pathol 2012, 36(6):799-807.
22. Dutta S, Wang F, Phalen A, Fishman DA Biomarkers for ovarian cancer detection and therapy. Cancer Biol & Ther 2010, 9(9):668-677.
23. Winter N, Nimzyk R, Bösche C, Meyer A, Bullerdiek J Chromatin immunoprecipitation to analyze DNA binding sites of HMGA2. PloS One 2011, 6(4):e18837.
24. Dahiya N, Morin PJ MicroRNAs in ovarian carcinomas. Endocrine-related Cancer 2010, 17(1):F77-F89.
25. Kobayashi E, Ueda Y, Matsuzaki S, Yokoyama T, Kimura T, Yoshino K, et al. Biomarkers for screening, diagnosis, and monitoring of ovarian cancer. Cancer Epidemiol Biomarkers & Prev 2012, 21(11):1902-1912.
26. Chung YW, Bae HS, Song JY, Lee JK, Lee NW, Kim T, et al. Detection of microrna as novel biomarkers of epithelial ovarian cancer from the serum of ovarian cancer patient. Intl J Gynecol Cancer 2013, 23(4):673-679.
27. Karve TM, Li X, Saha T BRCA1-mediated signaling pathways in ovarian carcinogenesis. Functional & Integrative Genomics 2012, 12(1):63-79.
28. Wan SM, Lv F, Guan T Identification of genes and microRNAs involved in ovarian carcinogenesis. Asian Pac J Cancer Prev 2012, 13:3997-4000.
29. Natarajan S, Hombach-Klonisch S, Dröge P, Klonisch T HMGA2 inhibits apoptosis through interaction with ATR-CHK1 signaling complex in human cancer cells. Neoplasia (NY) 2013, 15(3):263.
30. Ueda T, Volinia S, Okumura H, Shimizu M, Taccioli C, Rossi S, et al. Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol 2010, 11(2):136-146.